G
Genome Company
Innovative biologics for global healthcare, pioneering treatments beyond existing medicines
About Genome Company
Genome Company is a biotechnology firm specializing in the development of innovative biologics aimed at addressing unmet medical needs. Operating in the global healthcare market, the company focuses on creating new treatment possibilities that go beyond traditional medicines. Genome Company serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around the research, development, and commercialization of novel biologics, generating revenue through product sales, licensing agreements, and partnerships. The company's pipeline includes a variety of promising candidates such as GEN 001, SB 121, and GEN 501, which target different therapeutic areas. By adhering to core values of brave innovation and growth for all, Genome Company aspires to make a positive impact on global health.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 49
- Open positions
- None listed
- Dealroom signal
- 35.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Drug Development, DNA, Genetics and genomics, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Investment activity
- 1 company, latest Aug 2020
- Capital deployed
- $27M
- Preferred round
- SERIES B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| CONVERTIBLEOther financing | Mar 2026 | $25M | — | C-QUADRAT · Dongkoo Bio&Pharma · Brain Asset Management · Welcome Asset Management | ↗ |
| LATE VCOther financing | Apr 2023 | $77M | $306M | Undisclosed | — |
Growth signals
Latest recorded traffic for Genome Company is 3.9K monthly website visits, down 54.7% over the last three months. Genome Company's team declined 2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Genome Company in the Seongnam-si ecosystem
The Genome Company office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Korea Investment Partners
Korea Omega Investment
Paratus Investment
C-QUADRAT
Dongkoo Bio&Pharma
Brain Asset Management- WMWelcome Asset Management
- NMNH Hedge Asset Management
- SMSuseong Asset Management
Series B and later1 investor entered at this stage
DSC Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Genome Company on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genome Company’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











